The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2023

Filed:

Feb. 10, 2022
Applicant:

Baylor College of Medicine, Houston, TX (US);

Inventors:

Bert W. O'Malley, Houston, TX (US);

Sang Jun Han, Houston, TX (US);

David M. Lonard, Houston, TX (US);

Bryan Nikolai, Houston, TX (US);

Prashi Jain, Houston, TX (US);

Yosef Gilad, Houston, TX (US);

Clifford Dacso, Houston, TX (US);

Assignee:

Baylor College of Medicine, Houston, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 5/0637 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.


Find Patent Forward Citations

Loading…